Klump Michael A 4
4 · CytoDyn Inc. · Filed May 10, 2019
Insider Transaction Report
Form 4
CytoDyn Inc.CYDY
Klump Michael A
Director
Transactions
- Exercise/Conversion
Warrant (Right to Buy)
2019-05-08−500,000→ 0 total(indirect: See Footnote)Exercise: $0.30From: 2019-01-08Exp: 2024-01-08→ Common Stock (500,000 underlying) - Award
Warrant (Right to Buy)
2019-05-08+66,667→ 66,667 total(indirect: By Trust)Exercise: $0.40From: 2016-12-12Exp: 2021-12-12→ Common Stock (66,667 underlying) - Disposition to Issuer
Warrant (Right to Buy)
2019-05-08−125,000→ 0 totalExercise: $1.35From: 2016-04-26Exp: 2021-04-26→ Common Stock (125,000 underlying) - Exercise/Conversion
Common Stock
2019-05-08$0.40/sh+1,933,333$773,333→ 9,967,853 total(indirect: See Footnote) - Exercise/Conversion
Common Stock
2019-05-08$0.40/sh+125,000$50,000→ 125,000 total - Exercise/Conversion
Warrant (Right to Buy)
2019-05-08−125,000→ 0 totalExercise: $0.40From: 2016-04-26Exp: 2021-04-26→ Common Stock (125,000 underlying) - Exercise/Conversion
Common Stock
2019-05-08$0.40/sh+1,000,000$400,000→ 8,034,520 total(indirect: See Footnote) - Exercise/Conversion
Common Stock
2019-05-08$0.30/sh+500,000$150,000→ 10,467,853 total(indirect: See Footnote) - Exercise/Conversion
Common Stock
2019-05-08$0.40/sh+66,667$26,667→ 66,667 total(indirect: By Trust) - Award
Common Stock
2019-05-08+1,716,666→ 12,184,519 total(indirect: See Footnote) - Award
Common Stock
2019-05-08+33,333→ 100,000 total(indirect: By Trust) - Award
Common Stock
2019-05-08+62,500→ 187,500 total - Disposition to Issuer
Warrant (Right to Buy)
2019-05-08−1,000,000→ 0 total(indirect: See Footnote)Exercise: $0.75From: 2018-02-16Exp: 2023-02-16→ Common Stock (1,000,000 underlying) - Award
Warrant (Right to Buy)
2019-05-08+1,000,000→ 1,000,000 total(indirect: See Footnote)Exercise: $0.40From: 2018-02-16Exp: 2023-02-16→ Common Stock (1,000,000 underlying) - Exercise/Conversion
Warrant (Right to Buy)
2019-05-08−1,000,000→ 0 total(indirect: See Footnote)Exercise: $0.40From: 2018-02-16Exp: 2023-02-16→ Common Stock (1,000,000 underlying) - Disposition to Issuer
Warrant (Right to Buy)
2019-05-08−1,933,333→ 0 total(indirect: See Footnote)Exercise: $1.00From: 2016-12-12Exp: 2021-12-12→ Common Stock (1,933,333 underlying) - Award
Warrant (Right to Buy)
2019-05-08+1,933,333→ 1,933,333 total(indirect: See Footnote)Exercise: $0.40From: 2016-12-12Exp: 2021-12-12→ Common Stock (1,933,333 underlying) - Exercise/Conversion
Warrant (Right to Buy)
2019-05-08−1,933,333→ 0 total(indirect: See Footnote)Exercise: $0.40From: 2016-12-12Exp: 2021-12-12→ Common Stock (1,933,333 underlying) - Disposition to Issuer
Warrant (Right to Buy)
2019-05-08−66,667→ 0 total(indirect: By Trust)Exercise: $1.00From: 2016-12-12Exp: 2021-12-12→ Common Stock (66,667 underlying) - Exercise/Conversion
Warrant (Right to Buy)
2019-05-08−66,667→ 0 total(indirect: By Trust)Exercise: $0.40From: 2016-12-12Exp: 2021-12-12→ Common Stock (66,667 underlying) - Award
Warrant (Right to Buy)
2019-05-08+125,000→ 125,000 totalExercise: $0.40From: 2016-04-26Exp: 2021-04-26→ Common Stock (125,000 underlying)
Footnotes (2)
- [F1]The reported securities of CytoDyn Inc. (the "Company") are held by Argonne Trading, LLC, a Georgia limited liability company ("Argonne Trading"). Argonne Capital Group, LLC, a Georgia limited liability company ("Argonne Capital"), is the sole member of Argonne Trading. Michael A. Klump is Manager, President and Chief Executive Officer of Argonne Capital. Mr. Klump disclaims beneficial ownership of the securities held by Argonne Trading, except to the extent of his pecuniary interest therein.
- [F2]On May 8, 2019, the Company entered into Warrant Exercise Agreements with Mr. Klump, Argonne Capital and the Klump Children's Gift Trust, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the "Warrants") to purchase shares of the Company's common stock, par value $0.001 per share ("Common Stock") beneficially owned by Mr. Klump, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants.